Safety of herpes zoster vaccination among inflammatory bowel disease patients being treated with anti-TNF medications

Alimentary Pharmacology and Therapeutics

Volumn 46, Issue 7, 2017, Pages 668-672

  Khan, N ^a,b   Shah, Y ^b   Trivedi, C ^b   Lewis, J D ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; GOLIMUMAB; INFLIXIMAB; MERCAPTOPURINE; TUMOR NECROSIS FACTOR ANTIBODY; VARICELLA ZOSTER VACCINE; TUMOR NECROSIS FACTOR;

ADULT; AGED; ARTICLE; CHARLSON COMORBIDITY INDEX; COHORT ANALYSIS; DRUG SAFETY; FEMALE; HEALTH CARE SYSTEM; HERPES ZOSTER; HUMAN; INFLAMMATORY BOWEL DISEASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION; UNITED STATES; VACCINATION; VERY ELDERLY; ANTAGONISTS AND INHIBITORS; RISK;

AGED; AGED, 80 AND OVER; COHORT STUDIES; FEMALE; HERPES ZOSTER; HERPES ZOSTER VACCINE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK; TUMOR NECROSIS FACTOR-ALPHA; VACCINATION;

EID: 85028966620     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.14257     Document Type: Article

References (23)

1. Thomas SL, Hall AJ. What does epidemiology tell us about risk factors for Herpes zoster? Lancet Infect Dis. 2004;4:26.
2. Brisson M, Edmunds W, Law B, et al. Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. Epidemiol Infect. 2001;127:305-314.
3. Yoshikawa TT, Schmader K. Herpes zoster in older adults. Clin Infect Dis. 2001;32:1481-1486.
4. Cohen JI. Clinical practice: Herpes zoster. N Engl J Med. 2013;369:255-263.
5. Yawn BP, Gilden D. The global epidemiology of herpes zoster. Neurology. 2013;81:928-930.
6. Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014;4:e004833.
7. Hales CM, Harpaz R, Ortega-Sanchez I, Bialek SR. Update on recommendations for use of herpes zoster vaccine. MMWR Morb Mortal Wkly Rep. 2014;63:729-731.
8. Gupta G, Lautenbach E, Lewis JD. Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2006;4:1483-1490.
9. Marehbian J, Arrighi HM, Hass S, Tian H, Sandborn WJ. Adverse events associated with common therapy regimens for moderate-to-severe Crohn's disease. Am J Gastroenterol. 2009;104:2524-2533.
10. Cullen G, Baden RP, Cheifetz AS. Varicella zoster virus infection in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:2392-2403.
11. Practices ACol. Recommended adult immunization schedule: United States. Ann Intern Med. 2011;154:168.
12. Rahier J, Magro F, Abreu C, et al. Second european evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2014;8:443-468.
13. Zhang J, Xie F, Delzell E, et al. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA. 2012;308:43-49.
14. Zhang J, Delzell E, Xie F, et al. The use, safety, and effectiveness of herpes zoster vaccination in individuals with inflammatory and autoimmune diseases: a longitudinal observational study. Arthritis Res Ther. 2011;13:R174.
15. The national center for veterans analysis and statistics (ncvas). 2012. Trends in the utilization of VA programs and services, Washington, DC. http://www.va.gov/vetdata/docs/quickfacts/Utilization-slideshow.pdf. Accessed April 2013.
16. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352:2271-2284.
17. Cheetham TC, Marcy SM, Tseng HF, et al. Risk of herpes zoster and disseminated varicella zoster in patients taking immunosuppressant drugs at the time of zoster vaccination. Mayo Clin Proc. 2015;90:865-873.
18. Long MD, Martin C, Sandler RS, Kappelman MD. Increased risk of herpes zoster among 108 604 patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2013;37:420-429.
19. Côté-Daigneault J, Peerani F, MacMahon E, Delaporte E, Rahier JF, Colombel JF. Management and prevention of herpes zoster in the immunocompromised inflammatory bowel disease patient: a clinical quandary. Inflamm Bowel Dis. 2016;22:2538-2547.
20. Strangfeld A, Listing J, Herzer P, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-α agents. JAMA. 2009;301:737-744.
21. Harpaz R, Ortega-Sanchez IR, Seward JF. Prevention of Herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2008;57:1-30.
22. Farraye FA, Melmed GY, Lichtenstein GR, Kane SV. ACG clinical guideline: preventive care in inflammatory bowel disease. Am J Gastroenterol. 2017;112:241-258.
23. Oxman MN, Levin MJ, Group SPS. Vaccination against herpes zoster and postherpetic neuralgia. J Infect Dis. 2008; 197: S228-S236.